Search clinical trials for: PD-L1 LNA (RO7191863)

Total 203 results

Hoffmann-La Roche

Active, not recruiting

A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B (Piranga)

Hepatitis B, Chronic

Taiwan, Canada, Korea, Republic of, Thailand, United Kingdom, China, United States, Bulgaria, Spain, New Zealand, Hong Kong, Romania, Chile, France
Zhongnan Hospital

Recruiting

Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Baodong Qin

Unknown

Effect of Chemotherapy on PD-L1 in NSCLC

Chemotherapy | Immunotherapy | PD-L1

China
Tatarstan Cancer Center

Unknown

Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer

Hereditary Breast Cancer

Russian Federation
Hoffmann-La Roche

Completed

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell

United Kingdom, Czechia, Germany, Poland, Spain, Switzerland
Shanghai Zhongshan Hospital

Recruiting

Gut Microbiota and Cancer Immunotherapy Response

Non-Small Cell Lung Cancer

China
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

Solid Tumor | Metastatic Cancer | Locally Advanced Solid Tumor

United States
Medical University of Vienna

Unknown

CTA Expression/Methylation and Response to Pembrolizumab of NSCLC Patients

Non Small Cell Lung Cancer

Austria
University Hospital, Angers

Completed

Exosomes Implication in PD1-PD-L1 Activation in OSAS (ExoSAS)

Cancer | Sleep Apnea Syndromes, Obstructive

France
Centre Leon Berard
NETRIS Pharma

Recruiting

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies (IMMUNONET)

Advanced Solid Tumors | Metastatic Solid Tumors

France
Thomas Marron

Recruiting

Dupilumab_Metastatic NSCLC

Metastatic Non-small Cell Lung Cancer

United States
Lars Møller Pedersen

Completed

Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma

Follicular Lymphoma

Denmark
Tongji Hospital
National Natural Science Foundation of China

Recruiting

Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study (NICCE)

Esophageal Squamous Cell Carcinoma | Neoadjuvant Therapies

China
Binhui Biopharmaceutical Co., Ltd.

Recruiting

oHSV2-PD-L1/CD3-BsAb Administered Via Intramural Injection

Solid Tumor

United States
Peking Union Medical College Hospital

Recruiting

Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Recruiting

NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carciNoma (NATION1907II)

Oesophageal Squamous Cell Carcinoma

China
Herlev and Gentofte Hospital
University of Copenhagen

Completed

A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma

Basal Cell Carcinoma

Denmark
Second Affiliated Hospital, School of Medicine,...

Recruiting

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer

China
Inge Marie Svane

Completed

Dual Vaccine Trial in Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia

Denmark
University Hospital, Montpellier

Completed

Impact of Immune Checkpoint Inhibitor Therapy on Type 2 Inflammation (ImmunEO)

Patients Recieving Anti-PD-1 or Anti-PD-L1 Immunotherapies

France
Lene Meldgaard Knudsen

Completed

Vaccination With PD-L1 Peptide Against Multiple Myeloma

Multiple Myeloma

Denmark
Sichuan University

Not yet recruiting

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Lene Meldgaard Knudsen
IO Biotech

Terminated

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Denmark
The Second Hospital of Nanjing Medical University

Unknown

Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

Primary Hepatocellular Carcinoma
Pharmassist Ltd
University of Athens

Active, not recruiting

Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma

Melanoma | Non Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

Greece
Naestved Hospital

Recruiting

Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.

Non-small Cell Lung Cancer | Malignant Pleural Effusion

Denmark
Shanghai Henlius Biotech

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

China
Sichuan University

Recruiting

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites | Malignant Peritoneal Effusion | Serous Cavity Metastatises

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NSCLC | Advanced Solid Tumor

United States, China
Sichuan University

Recruiting

Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis

Pleural Effusion, Malignant | Peritoneal Carcinoma Metastatic

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Sunshine Lake Pharma Co., Ltd.

Terminated

KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma

Advanced HCC

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Lymphoma | Tumor, Solid

China
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

Cervical Cancer | Advanced Solid Tumor

China
The Netherlands Cancer Institute
Bristol-Myers Squibb

Recruiting

18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC

NSCLC Stage IV

Netherlands
Wuxi People's Hospital

Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Cancer | PD-L1 Gene Mutation

China
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx

Solid Tumor

United States
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair Deficiency

United States
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France
Second Affiliated Hospital of Soochow University

Not yet recruiting

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Carcinoma | Solid Tumor

China
Chinese PLA General Hospital
LinkDoc Technology (Beijing) Co. Ltd.

Unknown

A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors

Advanced Solid Tumors

China
Shen Lin
NeoCura

Not yet recruiting

Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer

Gastric Cancer

China
Johannes Laengle, MD, PhD
Christian Doppler Laboratory Applied Metabolomics

Recruiting

PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer (PETNEC)

Oesophageal Cancer | Rectal Cancer Stage

Austria
Hunan Province Tumor Hospital

Completed

The Prediction Biomarkers of Survival Outcome for Severe Immune-related Hepatitis

Lung Cancer

China
Tongji Hospital
Wuhan University; Sun Yat-sen University; Wuhan Union Hospital, China

Suspended

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Pyrotech Therapeutics, Inc.

Recruiting

PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

United States
Second Affiliated Hospital of Soochow University
SciClone Pharmaceuticals

Recruiting

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Advanced Solid Tumor | Refractory Tumor

China
University Medical Center Groningen

Completed

PD-L1 PET Imaging in Melanoma Patients

Melanoma

Netherlands
Shanghai Chest Hospital

Recruiting

Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Non Small Cell Lung Cancer

China

Search clinical trials for: PD-L1 LNA (RO7191863)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations